[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-neuroendocine-neoplasms-pnets\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-neuroendocine-neoplasms-pnets":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100603452","risk-factors-prognosis-clinicopathological-and-metabolic-characteristics-of-eo--vs-lo-pannets-100603452",false,"NCT07136701","Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs","Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study","Inclusion Criteria:\n\n* 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.\n\nExclusion Criteria:\n\n* Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.","ALL","18 Years","85 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).\n\nThe main questions it aims to answer are:\n\nAre there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.\n\nParticipants will:\n\nProvide retrospective clinical, pathological, and metabolic data from hospital records.\n\nHave survival and recurrence outcomes assessed through follow-up data review.",[25],"Pancreatic Neuroendocine Neoplasms (pNETs)",[27],"EO-PanNET","NOT_YET_RECRUITING","2025-08-21",{"date":31,"type":32},"2025-08-22","ACTUAL",{"date":34,"type":21},"2025-08-31",{"date":36,"type":21},"2027-07-31",{"name":38,"class":39},"Qilu Hospital of Shandong University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":40},"100573979","validation-of-joint-ai-in-diagnosing-pancreatic-solid-lesions-100573979","NCT06753318","Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions","Validation of a Multimodal Artificial Intelligence Model in in Diagnosing Pancreatic Solid Lesions: a Prospective, Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Imaging examinations (MRI, CT, B-ultrasound) show a solid mass in the pancreas, which requires endoscopic ultrasound guided-fine needle aspiration\u002Fbiopsy (EUS-FNA\u002FB) to clarify the nature of the lesion in patients.\n* Written consent provided\n\nExclusion Criteria:\n\n* Age under 18 years old",{"count":49,"type":21},716,"INTERVENTIONAL",[52],"NA","This clinical trial aims to learn if a multimodal artificial intelligence (AI) model can enhance the diagnosis of pancreatic solid lesions. The main questions it aims to answer are:\n\n1. Does the AI model enhance the diagnostic performance of endoscopists in diagnosing pancreatic solid lesions?\n2. Does the addition of interpretability analysis further improve the diagnostic performance of the assisted endoscopists? Researchers will compare the diagnostic performance of endoscopists with or without the assistance of the AI model.\n\nParticipants will:\n\n1. Their clinical data will be prospectively collected.\n2. They will be randomized to the AI-assist group and the conventional diagnosis group.",[55,56,25,57,58],"Pancreatic Cancer","Pancreatitis","Autoimmune Pancreatitis","Solid Pseudopapillary Neoplasm of the Pancreas",[60,61,62],"pancreatic cancer","artificial intelligence","endoscopic ultrasound","2024-12-22",{"date":65,"type":32},"2024-12-31",{"date":67,"type":21},"2025-01",{"date":69,"type":21},"2026-01",{"name":71,"class":39},"Huazhong University of Science and Technology"]